Emerald Organic Products Restructures Joint Venture Agreement with Todos Medical By Entering Joint Collaboration Agreement

Partnership Allows Both Companies to Focus on Their Core Strengths

HOLBROOK, NY, REHOVOT, ISRAEL, SINGAPORE AND NEW YORK, NY, May 08, 2020 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. (OTC: EMOR) ("Emerald") a diversified health sciences and technology company, is pleased to announce that further to  Emerald’s joint press release on March 24, 2020 regarding Corona Diagnostics, LLC (“Corona Diagnostics”), Emerald’s joint venture with Todos Medical Ltd. (OTC: TOMDF) (“Todos”) has been restructured into a new joint collaboration agreement with Todos (the “New Terms”). 

Under the New Terms, Todos will continue to validate and commercialize testing protocols for COVID-19, and Emerald will provide technological assistance and solutions through its digital pharmacy Bonsa Health, Inc. and telehealth platform Carie.com to help to establish virtual laboratory infrastructure to streamline COVID-19 testing protocols. 

“In light of  Emerald’s recent acquisitions of the Bonsa digital pharmacy and Carie.com telehealth platform, Emerald is able to add more value under this new collaboration agreement,” said Ian Parker, CEO of Emerald.  “Emerald believes that its digital health assets have the potential to be valuable parts of a comprehensive testing solution. Under the collaboration, we will support Todos’s efforts in providing a reliable and scalable testing regime by providing technology solutions that could potentially make such a testing regime more accessible and convenient.”  Parker added, “We are now starting to evaluate how we can add and optimize different workflows to connect physicians with authorized laboratories to assist Todos in getting much needed testing to the market.” 

“It’s our opinion that pharmacies are playing a critical role in helping to manage community healthcare during the COVID-19 pandemic,” said Parker. “Pharmacies are now able to collect specimens and administer COVID-19 antibody testing in certain states, which gives us the opportunity to activate our independent pharmacy network to help expand available testing in the United States.”

“At this critical moment in our country’s history, we need to increase COVID-19 testing capacity and make routine lab testing more accessible,” said Gerald Commissiong, CEO of Todos Medical. “In addition to COVID testing, patients and their doctors need access to convenient and routine lab testing so they can make sound health decisions. Virtual Laboratory could play an important role in this process by helping to streamline workflow for high complexity CLIA labs interfacing with physicians and payers so that labs can focus on getting COVID-19 testing capabilities scaled up appropriately.”